Premium
P3‐236: Novel biomarkers for the diagnosis of frontotemporal dementia
Author(s) -
Simonsen Anja H.,
Paraskevas George,
Kapaki Elisabeth,
Waldemar Gunhild
Publication year - 2010
Publication title -
alzheimer's and dementia
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 6.713
H-Index - 118
eISSN - 1552-5279
pISSN - 1552-5260
DOI - 10.1016/j.jalz.2010.05.1735
Subject(s) - frontotemporal dementia , disease , dementia , chromogranin a , frontotemporal lobar degeneration , medicine , differential diagnosis , psychology , oncology , clinical psychology , pathology , immunohistochemistry
(TMT) A and B, denomination (DO80), digit span tests, battery of frontal function were performed in AD patients. All patients gave their informed consent. CSF biomarkers (Ab 1-42, tau and p181 tau) were assessed after lumbar puncture in the month following cognitive tests. Spearman correlation coefficients between CSF biomarkers and the different cognitive tests were calculated. Generalized linear models adjusted for age, sex and level of education were used for multivariable analysis. Results: MMSE scores were inversely associated with the levels of CSF Ab 1-42 (Spearman’s rho 1⁄4 0.28, p 1⁄4 0.03) and TMT B scores were associated with tau (Spearman’s rho1⁄4 0.37, p1⁄4 0.02) and p181-tau (Spearman’s rho1⁄4 0.45, p1⁄4 0.004) CSF levels. These associations remained after adjustment for age, sex, and level of education in multivariable analysis. No correlation was observed with the other cognitive tests. Conclusions: Our results show that in a cohort of recently diagnosed AD patients, CSF biomarkers levels can correlate with the results of cognitive functions. A b 1-42 levels are linked to MMSE scores reflecting the global cognitive functions and tau and p181 tau CSF levels are correlated with executive functions assessed by the TMT B test.